Antengene Corporation announced that its in-house developed novel PD-L1/4-1BB bispecific antibody, ATG-101, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.
The Orphan Drug Designation will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101.
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.